We examined whether brain damage after focal cortex trauma may be attenuated by adenoviral delivery of the glial cell line-derived neurotrophic factor (GDNF) gene. For this reason, injections of vehicle, of an adenoviral vector deleted in the E1 region (Ad-dE1) or a vector expressing the GDNF gene from a CMV promoter (Ad-GDNF) were stereotactically placed in the rat sensorimotor cortex, and one day later cold lesions of the cerebral cortex were induced. Lesions were associated with pronounced brain swelling one day after injury. The degree of brain swelling was significantly attenuated by Ad-GDNF delivery (Ad-GDNF: 7.4 ؎ 2.2%, Ad-dE1: 21.1 ؎ 4.9%, vehicle: 20.9 ؎ 5.0% of contralateral; mean ؎ SEM, P < 0.05). Furthermore, Ad-GDNF treatment resulted in a significant reduction of the lesion volume seven days after lesioning (Ad-GDNF: 21.8 ؎ 2.8 mm 3 , Ad-dE1: 44.1 ؎ 1.6 mm 3 , vehicle 40.9 ؎ 8.6 mm 3 , P < 0.05). The decrease in the lesion size was associated with a reduction in the number of inducible nitric oxide (iNOS)(؉), activated caspase-3(؉) and DNA fragmented cells in the perilesion rim, as revealed by immunocytochemistry and terminal transferase biotinylated-dUTP nick end labeling (TUNEL). In Ad-GDNF-treated animals, the number of caspase-3(؉) and TUNEL(؉) cells was also reduced in the lesion-remote thalamus. The present study shows that adenoviral GDNF delivery is protective in focal cortex trauma.
INTRODUCTION
Brain trauma involves a complex pattern of features, such as cortical contusion, diffuse axonal injury and intracerebral bleeding, which are followed by secondary hemodynamic and metabolic disturbances resulting in an aggravation of injury and secondary lesion growth (Hovda et al., 1996; Dietrich et al., 1998) . We previously examined pathophysiological changes in the surroundings of a cold lesion (Hermann et al., 1998 (Hermann et al., , 1999a (Hermann et al., , 1999b , which is a model of a focal cortex trauma (Chan et al., 1991; Morita-Fujimura et al., 1999 , 2000 . We showed that cortex injury is followed by widespread alterations in regional pH and in tissue glucose and lactate contents, which are closely associated with vasogenic edema and intimately related to secondary tissue damage (Hermann et al., 1998 (Hermann et al., , 1999a .
During the last few years, viral gene transfer techniques have achieved increasing interest in the treatment of neurodegenerative diseases (Bilang-Bleuel et al., 1997; Gravel et al., 1997; Ribotta et al., 1997; Mandel et al., 1999; Kitagawa et al., 1999; Hermann et al., 2001) . The major advantage of this approach is that the delivered peptides are continuously synthesized directly at their site of action, which reduces the possibility that effects are compromized due to fluctuations of supply and at the same time limits systemic side effects. We recently showed that the secondary degeneration of axotomized retinal ganglion cells may be prevented by adenoviral delivery of neurotrophic factors (Isenmann et al., 1998; Weise et al., 2000) .
